

# Tau protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/T50CBDDDECB8EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T50CBDDDECB8EN

## Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Tau protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Tau protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Tau protein inhibitors Understanding

#### Tau protein inhibitors: Overview

Tau proteins are proteins that perform the function of stabilizing microtubules. These proteins are abundant in nerve cells and are present to a much lesser degree in oligodendrocytes and astrocytes. When Tau proteins become defective and fail to adequately stabilize microtubules, pathologies of the nervous system can develop such as Alzheimer's disease.

Function - Tau proteins are mainly active in the distal portions of axons where they stabilize microtubules as well as providing flexibility. The proteins work together with a globular protein called tubulin to stabilize microtubules and aid the assembly of tubulin in the microtubules. Tau proteins achieve their control of microtubule stability through

isoforms and phosphorylation. Hyperphosphorylation of tau proteins can cause the helical and straight filaments to tangle (referred to as neurofibrillary tangles). These tangles contribute to the pathology of Alzheimer's disease.

Tau protein inhibitors - Alzheimer disease is characterized by pathological aggregation of two proteins, tau and A $\beta$ -amyloid, both of which are considered to be toxic to neurons. Recent advances have shown small molecule inhibitors of protein aggregation with emphasis on tau, with activities mediated by the direct interference of self-assembly. The inhibitors can be clustered in several compound classes according to their chemical structure, with subsequent description of the structure–activity relationships, showing that hydrophobic interactions are prevailing.

### Tau protein inhibitors Emerging Drugs Chapters

This segment of the Tau protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Tau protein inhibitors Emerging Drugs

#### R-phenserine: Annovis Bio

R-enantiomer (positive isomer) of phenserine, being developed by Annovis Bio (formerly QR Pharma), under a licence from Horizon Therapeutics plc (formerly Horizon Pharma), for the treatment of Alzheimer's disease (AD) and dementia in Down syndrome (AD-DS), Parkinson's disease (PD), stroke and traumatic brain injuries. Currently, it is in phase 2 of development stage for the treatment of Mild cognitive impairment.

#### Bepranemab: UCB

Bepranemab (also known as UCB 0107) is a recombinant, humanised, full length IgG4 monoclonal antibody targeting a central tau epitope, being developed by UCB pharma for the treatment of Alzheimer's disease; Progressive supranuclear palsy. Currently, it is in phase 1 stage of development.

## Hydromethylthionine mesylate (TRx-0237): TauRx Pharmaceuticals

Hydromethylthionine mesylate (TRx 0237) is an orally available, second-generation inhibitor of tau protein aggregation and TDP-43 aggregation being developed by TauRx Pharmaceuticals and is currently in phase 3 stage of development for the treatment of Alzheimer's disease and Dementia.

Further product details are provided in the report.....

### Tau protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Tau protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on Tau protein inhibitors

There are approx. 15+ key companies which are developing the Tau protein inhibitors. The companies which have their Tau protein inhibitors drug candidates in the most advanced stage, i.e. phase III include, TauRx Pharmaceuticals.

#### Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

Tau protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Tau protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau protein inhibitors therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau protein inhibitors drugs.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tau protein inhibitors R&D. The therapies under development are focused on novel approaches for Tau protein inhibitors.

### Tau protein inhibitors Report Insights

Tau protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Tau protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Tau protein inhibitors drugs?

How many Tau protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Tau protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tau protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Tau protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Annovis Bio

UCB Biopharma

TauRx Pharmaceuticals

Voyager Therapeutics

Oligomerix

APRINOIA Therapeutics

Sangamo Therapeutics

AC Immune

Eli Lilly and Company

Denali Therapeutics Inc

Takeda

TAU BIO-LOGIC

VITRUVIAN BioMedical

BeyondBio

DTx Pharma

Eisai Co Ltd

reMYND

Dong-A ST

## Key Products

R-phenserine

Bepranemab

Hydromethylthionine mesylate (TRx-0237)

Vectorized tau antibodies

ST 501

ACI 3024

AT 8 antibody

ATV:BACE1/Tau

TBL 100

YM 7555

BEY-2153

MSUT2 programme

E 2814

ReS19 T

NB 02



## Contents

- Introduction
- Executive Summary
- Tau protein inhibitors: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Tau protein inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
  - Tau protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value
- Trends
- Tau protein inhibitors Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- TRx-0237: TauRx Pharmaceuticals
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- R-phenserine : Annovis Bio
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
  - Comparative Analysis

Bepranemab: UCB

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

NB 02: Dong-A ST

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Tau protein inhibitors Key Companies

Tau protein inhibitors Key Products

Tau protein inhibitors- Unmet Needs

Tau protein inhibitors- Market Drivers and Barriers

Tau protein inhibitors- Future Perspectives and Conclusion

Tau protein inhibitors Analyst Views

Tau protein inhibitors Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Tau protein inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Tau protein inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Tau protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/T50CBDDDECB8EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T50CBDDDECB8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970